| Date | Time | Room | Session Title | Presentation Time | Topic | Role |
|---|---|---|---|---|---|---|
| 2022-06-05 | 08:56 to 10:08 | BRAVS ROOM |
CLINICAL AND SURGICAL RETINA Debate - BRAVS DEBATE (34) |
09:05 to 09:08 | Risk / Benefit Ratio for Brolucizumab Is acceptable: | Presenter |